An interventional study of meaningful activities and other activities in Old Age; Dementia and Old Age; Debility, sponsored by Universidad de Burgos. Recruiting at 1 site in Spain. Open to male participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2024-10-02.
Sponsored by Universidad de Burgos · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 279 studies in Alzheimer Disease with a site in Spain — 54 open to participants now, 80 under way, 24 of them phase 3. Alzheimer Disease · Spain.
Among the 279 studies in Alzheimer Disease with a site in Spain, this one is the 234th largest by planned enrollment of the 240 interventional ones that give a count, is one of 20 that started in 2024, is one of 66 with no phase, reaches primary completion later than 2 of the 79 other live ones, and was the 232nd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →54 of the 279 studies in Alzheimer Disease with a site in Spain are open now. Recruiting first, the newest first:
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation · Sites in Spain
Ages 55–85
Sanofi · Sites in Spain, United States, Australia and 4 more countries
Ages 55–85
Eidos Therapeutics, a BridgeBio company · Sites in Spain, United States, Singapore
Ages 18–80
Stichting International Registry for Alzheimer's Disease and other Dementias Foundation · Sites in Spain, Australia, Austria and 14 more countries
Ages 18+
Exciva GmbH · Sites in Spain, United States, Canada and 6 more countries
Ages 55–90
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 60 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
279 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 81 · Phase 3 94 · Phase 4 4
First in 2002; this study’s year is marked. 20 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10 is below the median of 70 across 3,022 interventional studies indexed under Alzheimer Disease.
Median enrollment 258 across the 240 interventional studies, 400 across the 39 observational. Of the 187 that completed or were terminated, 91 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
178 of 279 have an industry lead sponsor. The 10 most frequent:
Universidad de Burgos is the lead sponsor of 25 studies on the registry; 4 are open to participants now.
Universidad de Burgos has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
20 of the studies in Alzheimer Disease with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT07682155Germans Trias i Pujol HospitalStudy of the Brain's Natural Cleaning System in Potential Organ Donors. | 2026-11-30 |
| NCT07639645University of ValenciaIntervention to Reduce Unwanted Loneliness in Family Caregivers of People With Alzheimer | 2026-12 |
Add all 20 to your calendar (.ics) → With an account.
Among the 279 studies in Alzheimer Disease with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The increasing life expectancy and global aging population necessitate changes in long-term gerontological services based on Person-Centred Care approaches. This study aims to improve Person-Centred Care in geriatric centers through meaningful activities and the role of occupational therapists and direct care professionals in developing these activities. A descriptive cross-sectional quasi-experimental design was proposed, with 10 participants.
Background: Increasing life expectancy means that the ageing of populations globally is on the rise. It is therefore important to promote changes in long-term gerontological services based on Person-Centred Care approaches, in which meaningful occupation serves as a basis and is supported by appropriate professional support, such as the occupational therapist and the direct care professional.
Objective: To improve Person-Centred Care in a geriatric centre, through the use of meaningful activities and to identify the role of the occupational therapist and direct care professional in the development of these activities.
Methods: A descriptive cross-sectional quasi-experimental pre-post single-group design is proposed. A total of 10 participants. The methodology used will be mixed. The data collection techniques and tools will be the PDC evaluation instrument pre and post intervention and a survey at the end of the project.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The intervention proposal will be developed in a module with 10 elderly people, all of them men, with moderate dependence and older, with an average age of 84 years. All of them have multiple medical pathologies with the need for continuous nursing care.
Other: meaningful activities
The intervention proposal will be developed in a module with 10 elderly people, all of them men, with moderate dependence and older, with an average age of 84 years. All of them have multiple medical pathologies with the need for continuous nursing care.
Other: other activities
The intervention proposal will be developed in a module with 27 elderly people, all of them men, with moderate dependence and older, with an average age of 84 years. All of them have multiple medical pathologies with the need for continuous nursing care.
The intervention proposal will be developed in a module with 27 elderly people, all of them men, with moderate dependence and older, with an average age of 84 years. All of them have multiple medical pathologies with the need for continuous nursing care.
Kruskal-Wallis test
To compare the medians of the groups
Time frame: 3 months
Spearman's correlation coefficient
This measure allows us to determine the strength and direction of the association between the variables
Time frame: 3 months
Plan to share: No — Although each participant will provide their name and email address to register for the study, their data and survey results will be completely anonymous and linked to a participant code. On each measurement occasion, participants will be emailed a link to the survey and, when clicked, will be taken to the google-forms web platform that will host the surveys. The web surveys will not ask for any information that can be used to identify a specific participant, and google-forms will not record any metadata.
Started Sep 2024 (actual). Primary completion is estimated for Dec 2024, 2 months after the start.
Of 887 non-industry interventional studies with no phase under Alzheimer Disease, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 51. This study's planned 2 months is below that.
Counting every sponsor, half of 964 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad de Burgos